MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 01-26-2023
Myovant Sciences Ltd. Operating Cycle 2011-2026 | MYOV
Annual Operating Cycle Myovant Sciences Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 | 11 | 11 |
Quarterly Operating Cycle Myovant Sciences Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 4.79 | 4.8 | - | 27.9 | 6.58 | 5.44 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34 | 4.79 | 13.9 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 15.46 | - | $ 49.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.11 | - | $ 646 M | USA |
 |
Exelixis
EXEL
|
140 | $ 44.42 | - | $ 12.1 B | USA |
 |
Fortress Biotech
FBIO
|
325 | $ 2.46 | - | $ 68.6 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
148 | $ 6.72 | - | $ 192 M | USA |
 |
Hutchison China MediTech Limited
HCM
|
134 | $ 13.3 | - | $ 11.4 B | China |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Immuron Limited
IMRN
|
1.46 K | $ 0.79 | - | $ 8.53 M |  Australia |
 |
INmune Bio
INMB
|
19.9 K | $ 1.54 | - | $ 38.1 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
259 | $ 75.25 | - | $ 12 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
213 | $ 26.71 | - | $ 1.44 B | Britain |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.35 | - | $ 3.7 B | USA |
 |
Kamada Ltd.
KMDA
|
269 | $ 8.21 | - | $ 260 M |  Israel |
 |
Galapagos NV
GLPG
|
149 | $ 28.39 | - | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.27 | - | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 105.81 | - | $ 5.31 B | USA |
 |
MannKind Corporation
MNKD
|
457 | $ 2.86 | - | $ 874 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.42 | - | $ 2.98 B | USA |